Amgen price target lowered to $131 from $139 at Citigroup Citigroup lowered its price target for Amgen shares to $131 after dropping its estimates for the company's myeloma drug Kyprolis to below consensus. Citi believes the drug's inconvenience and cardiac toxicities are limiting its uptake and while drugs in late stage development offer far more appealing profiles. Citi, however, keeps a Buy rating on Amgen.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.